Objective: To compare the treatment efficacy of methylphenidate and atomoxetine on core symptoms, behavioral and emotional problems, and executive function in children with attention-deficit/hyperactivity disorder (ADHD). Methods: Sixty children with ADHD diagnosed by the fifth edition Diagnostic and Statistical Manual of Mental Disorders in Tangshan Maternal and Child Health Hospital from 2023 to 2024 were randomly divided into methylphenidate and atomoxetine groups. Core symptoms were assessed using the Parent Swanson, Nolan, and Pelham, Version IV Scale (SNAP-IV) and Integrated Visual and Auditory Continuous Performance Test (IVA-CPT). Behavioral and emotional problems were administered via the Conners Parent Symptom Questionnaire (PSQ) and executive function was evaluated utilizing the Wisconsin Card Sorting Test (WCST) and Digit Span Test (DST). All data were analyzed using SPSS 26.00 to identify discrepancies. Results: When contrasted with the methylphenidate and atomoxetine groups at 12 weeks, their mean efficiency was no significant disparity (p>0.05). Notable statistical differences were evident in IVA-CPT, the inattention, hyperactivity-impulsivity of SNAP-IV, and the psychosomatic disorder, anxiety, and hyperactivity-impulsivity of PSQ (p<0.05), yet in hyperactivity index, conduct, and learning difficulties of PSQ (p>0.05). No statistical significance was attributed to DST and the number of completed categories in WCST (p>0.05) but to response errors and perseverative errors (p<0.05). Conclusion Although both methylphenidate and atomoxetine are capable of effectively ameliorating ADHD, methylphenidate demonstrates a superior ability to improve core symptoms of ADHD, as well as address conduct problems, cognitive transfer abilities, and frontal lobe function in pediatric patients. Conversely, atomoxetine is the best choice for cases comorbid with anxiety.

Objective: To compare the treatment efficacy of methylphenidate and atomoxetine on core symptoms, behavioral and emotional problems, and executive function in children with attention-deficit/hyperactivity disorder (ADHD). Methods: Sixty children with ADHD diagnosed by the fifth edition Diagnostic and Statistical Manual of Mental Disorders in Tangshan Maternal and Child Health Hospital from 2023 to 2024 were randomly divided into methylphenidate and atomoxetine groups. Core symptoms were assessed using the Parent Swanson, Nolan, and Pelham, Version IV Scale (SNAP-IV) and Integrated Visual and Auditory Continuous Performance Test (IVA-CPT). Behavioral and emotional problems were administered via the Conners Parent Symptom Questionnaire (PSQ) and executive function was evaluated utilizing the Wisconsin Card Sorting Test (WCST) and Digit Span Test (DST). All data were analyzed using SPSS 26.00 to identify discrepancies. Results: When contrasted with the methylphenidate and atomoxetine groups at 12 weeks, their mean efficiency was no significant disparity (p>0.05). Notable statistical differences were evident in IVA-CPT, the inattention, hyperactivity-impulsivity of SNAP-IV, and the psychosomatic disorder, anxiety, and hyperactivity-impulsivity of PSQ (p<0.05), yet in hyperactivity index, conduct, and learning difficulties of PSQ (p>0.05). No statistical significance was attributed to DST and the number of completed categories in WCST (p>0.05) but to response errors and perseverative errors (p<0.05). Conclusion Although both methylphenidate and atomoxetine are capable of effectively ameliorating ADHD, methylphenidate demonstrates a superior ability to improve core symptoms of ADHD, as well as address conduct problems, cognitive transfer abilities, and frontal lobe function in pediatric patients. Conversely, atomoxetine is the best choice for cases comorbid with anxiety.

Objective: To compare the treatment efficacy of methylphenidate and atomoxetine on core symptoms, behavioral and emotional problems, and executive function in children with attention-deficit/hyperactivity disorder (ADHD). Methods: Sixty children with ADHD diagnosed by the fifth edition Diagnostic and Statistical Manual of Mental Disorders in Tangshan Maternal and Child Health Hospital from 2023 to 2024 were randomly divided into methylphenidate and atomoxetine groups. Core symptoms were assessed using the Parent Swanson, Nolan, and Pelham, Version IV Scale (SNAP-IV) and Integrated Visual and Auditory Continuous Performance Test (IVA-CPT). Behavioral and emotional problems were administered via the Conners Parent Symptom Questionnaire (PSQ) and executive function was evaluated utilizing the Wisconsin Card Sorting Test (WCST) and Digit Span Test (DST). All data were analyzed using SPSS 26.00 to identify discrepancies. Results: When contrasted with the methylphenidate and atomoxetine groups at 12 weeks, their mean efficiency was no significant disparity (p>0.05). Notable statistical differences were evident in IVA-CPT, the inattention, hyperactivity-impulsivity of SNAP-IV, and the psychosomatic disorder, anxiety, and hyperactivity-impulsivity of PSQ (p<0.05), yet in hyperactivity index, conduct, and learning difficulties of PSQ (p>0.05). No statistical significance was attributed to DST and the number of completed categories in WCST (p>0.05) but to response errors and perseverative errors (p<0.05). Conclusion Although both methylphenidate and atomoxetine are capable of effectively ameliorating ADHD, methylphenidate demonstrates a superior ability to improve core symptoms of ADHD, as well as address conduct problems, cognitive transfer abilities, and frontal lobe function in pediatric patients. Conversely, atomoxetine is the best choice for cases comorbid with anxiety.

Objective: To compare the treatment efficacy of methylphenidate and atomoxetine on core symptoms, behavioral and emotional problems, and executive function in children with attention-deficit/hyperactivity disorder (ADHD). Methods: Sixty children with ADHD diagnosed by the fifth edition Diagnostic and Statistical Manual of Mental Disorders in Tangshan Maternal and Child Health Hospital from 2023 to 2024 were randomly divided into methylphenidate and atomoxetine groups. Core symptoms were assessed using the Parent Swanson, Nolan, and Pelham, Version IV Scale (SNAP-IV) and Integrated Visual and Auditory Continuous Performance Test (IVA-CPT). Behavioral and emotional problems were administered via the Conners Parent Symptom Questionnaire (PSQ) and executive function was evaluated utilizing the Wisconsin Card Sorting Test (WCST) and Digit Span Test (DST). All data were analyzed using SPSS 26.00 to identify discrepancies. Results: When contrasted with the methylphenidate and atomoxetine groups at 12 weeks, their mean efficiency was no significant disparity (p>0.05). Notable statistical differences were evident in IVA-CPT, the inattention, hyperactivity-impulsivity of SNAP-IV, and the psychosomatic disorder, anxiety, and hyperactivity-impulsivity of PSQ (p<0.05), yet in hyperactivity index, conduct, and learning difficulties of PSQ (p>0.05). No statistical significance was attributed to DST and the number of completed categories in WCST (p>0.05) but to response errors and perseverative errors (p<0.05). Conclusion Although both methylphenidate and atomoxetine are capable of effectively ameliorating ADHD, methylphenidate demonstrates a superior ability to improve core symptoms of ADHD, as well as address conduct problems, cognitive transfer abilities, and frontal lobe function in pediatric patients. Conversely, atomoxetine is the best choice for cases comorbid with anxiety.

Objective: To compare the treatment efficacy of methylphenidate and atomoxetine on core symptoms, behavioral and emotional problems, and executive function in children with attention-deficit/hyperactivity disorder (ADHD). Methods: Sixty children with ADHD diagnosed by the fifth edition Diagnostic and Statistical Manual of Mental Disorders in Tangshan Maternal and Child Health Hospital from 2023 to 2024 were randomly divided into methylphenidate and atomoxetine groups. Core symptoms were assessed using the Parent Swanson, Nolan, and Pelham, Version IV Scale (SNAP-IV) and Integrated Visual and Auditory Continuous Performance Test (IVA-CPT). Behavioral and emotional problems were administered via the Conners Parent Symptom Questionnaire (PSQ) and executive function was evaluated utilizing the Wisconsin Card Sorting Test (WCST) and Digit Span Test (DST). All data were analyzed using SPSS 26.00 to identify discrepancies. Results: When contrasted with the methylphenidate and atomoxetine groups at 12 weeks, their mean efficiency was no significant disparity (p>0.05). Notable statistical differences were evident in IVA-CPT, the inattention, hyperactivity-impulsivity of SNAP-IV, and the psychosomatic disorder, anxiety, and hyperactivity-impulsivity of PSQ (p<0.05), yet in hyperactivity index, conduct, and learning difficulties of PSQ (p>0.05). No statistical significance was attributed to DST and the number of completed categories in WCST (p>0.05) but to response errors and perseverative errors (p<0.05). Conclusion Although both methylphenidate and atomoxetine are capable of effectively ameliorating ADHD, methylphenidate demonstrates a superior ability to improve core symptoms of ADHD, as well as address conduct problems, cognitive transfer abilities, and frontal lobe function in pediatric patients. Conversely, atomoxetine is the best choice for cases comorbid with anxiety.

Objective: To explore the prevalence and relevant factors of physical and emotional abuse by parents among children with autism spectrum disorder (ASD), so as to provide basis for intervention program of children abuse. Methods: A total of 221 ASD children from 3 special education institutions in Tangshan were investigated from March to October in 2021, 395 non ASD children from two kindergartens in urban and rural areas were selected by convenient sampling. Parents of these children were invited for online and on site questionnaire survey. The self designed violence questionnaire, Childhood Autism Rating Scale and Patient Health Questionnaire-9 were used to assess violence, severity of autism, depression of parents. Chi square test, Fisher s exact probability method and Logistic regression were used to analyze the influencing factors of violence. Results: About 81.9% of children with ASD and 72.9% of non ASD children experienced violence( P <0.05). The reported rates of physical and emotional violence in ASD children were 74.2% and 73.8% respectively, which in non ASD children were 58.7% and 65.8% respectively. There were significant differences in the 3 types of violence rate between the two groups ( P <0.05). Multivariate Logistic regression analysis showed that boys ( OR =1.70, 95% CI =1.12-2.60), annual per capita income <10 000 yuan( OR =2.43, 95% CI =1.45- 4.08 ), and parental depression ( OR mild =11.01, 95% CI =5.38-22.49; OR moderate =69.97，95% CI =24.25-201.93) were the risk factors for child violence exposure; ASD disease ( OR=1.96，95%CI =1.32-2.92), older age ( OR=1.19, 95%CI =1.01-1.41) and parental depression( OR mild =7.83, 95% CI =3.67-16.74; OR moderate =14.37，95% CI =6.17-33.46) were risk factors for physical violence; boys ( OR =1.62, 95% CI =1.11-2.36), mothers who work in manual labor ( OR=1.68, 95%CI =1.09-2.59) and parental depression ( OR mild =7.69, 95% CI =3.74-15.81; OR moderate =25.37, 95% CI =10.80-59.63) were risk factors for emotional violence( P < 0.05 ). Conclusion The reported rate of parental violence against children with ASD is high. Mental health promotion and social support for families with ASD should be strengthened.